[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiac-allograft-vasculopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiac-allograft-vasculopathy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,60,91,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100522966","mariner-trial-multiparametric-cardiac-pet-for-cav-surveillance-after-heart-transplantation-100522966",false,"NCT06089486","MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation","Multiparametric Cardiac Positron Emission Tomography for Cardiac Allograft Vasculopathy Surveillance After Heart Transplantation","Inclusion Criteria:\n\n1. Post heart transplant 2-10 years.\n2. Age ≥18 years.\n3. Able to provide informed consent.\n\nExclusion Criteria:\n\n1. Contraindication to dipyridamole due to severe aortic stenosis.\n2. Contraindication to dipyridamole due to 2:1 or greater AV block without pacemaker.\n3. Contraindication to dipyridamole due to severe bronchospasm.\n4. Unable to undergo coronary angiography due to allergy to iodinated contrast.\n5. Unable to undergo coronary angiography due to glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2. for non-dialysis patients as determined by local laboratory analysis.\n6. Unable to undergo coronary angiography due to unsuitable vascular access.\n7. Treated rejection ≤1-month.\n8. Unstable angina or MI ≤7 days.","ALL","18 Years",{"count":19,"type":20},576,"ESTIMATED","INTERVENTIONAL",[23],"NA","Cardiac allograft vasculopathy (CAV) is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. Surveillance for CAV is vital; however an ideal approach has not been established. The goal of this study is to assess whether noninvasive positron emission tomography (PET) based surveillance is non-inferior to invasive coronary angiography (ICA) surveillance.",[26],"Cardiac Allograft Vasculopathy",[28],"Heart Transplant","RECRUITING","2026-04-29",{"date":32,"type":33},"2026-05-06","ACTUAL",{"date":35,"type":33},"2024-01-08",{"date":37,"type":20},"2029-03",{"name":39,"class":40},"Ottawa Heart Institute Research Corporation","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":54,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":58,"locationsCount":59},"100421608","phase-3-aerial-trial-antiplatelet-therapy-in-heart-transplantation-100421608","NCT04770012","AERIAL Trial: Antiplatelet Therapy in Heart Transplantation","Early Initiation of Antiplatelet ThERapy In HeArt TranspLantation: AERIAL Trial","Inclusion Criteria:\n\n1. Heart transplant\n2. Age ≥18 years\n3. Able to provide informed consent\n\nExclusion Criteria:\n\n1. Allergy or known intolerance to aspirin\n2. Allergy or known intolerance to clopidogrel\n3. Intracranial hemorrhage ≤14 days\n4. Bleeding disorder\n5. Platelet count \\\u003C50 x 109\u002FL\n6. History of aspirin related gastrointestinal bleeding or ulcers\n7. Non-cardiac indication for antiplatelet therapy\n8. Anticoagulation \\>3 months\n9. Allergy to iodinated contrast\n10. Unable to undergo coronary angiography due to glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2 for non-dialysis patients\n11. Unable to undergo coronary angiography due to unsuitable vascular access\n12. Combined solid organ transplantation.",{"count":49,"type":20},135,[51],"PHASE3","Cardiac allograft vasculopathy is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. The research team is investigating whether early antiplatelet therapy post heart transplant can prevent the development of CAV. This study will determine the feasibility of a large multicenter randomized placebo-controlled trial to answer this question.",[26,28],{"date":32,"type":33},{"date":56,"type":33},"2021-06-28",{"date":37,"type":20},{"name":39,"class":40},3,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":68,"targetDuration":70,"studyType":71,"phases":4,"briefSummary":72,"conditions":73,"keywords":74,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100594484","comparing-pcct-with-ica-and-ivus-in-detecting-cardiac-allograft-vasculopathy-100594484","NCT07020039","Comparing PCCT With ICA and IVUS in Detecting Cardiac Allograft Vasculopathy","Comparing Photon Counting Computed Tomography With Invasive Coronary Angiography and Intravascular Ultrasound in Detecting Cardiac Allograft Vasculopathy","CAVIAR","Inclusion Criteria:\n\n* Adult heart transplant recipients.\n* Clinically stable and scheduled for routine ICA.\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Contrast allergy\n* Renal insufficiency with eGFR \\\u003C 30 ml\u002Fmin\u002Fm2\n* Other contraindications for PCCT, ICA, or IVUS\n* Acute cardiac events within 30 days prior to enrollment.",{"count":69,"type":20},100,"3 Days","OBSERVATIONAL","In traditional coronary artery disease, patients often experience symptoms such as angina. However, heart transplant patients lack nerve connections in the transplanted heart and therefore usually do not notice any symptoms. For this reason, routine examinations are performed using traditional coronary angiography at one, three, and six years after transplantation, sometimes with the addition of coronary ultrasound.\n\nA new technique, photon-counting computed tomography, has now been developed and may potentially replace both traditional coronary angiography and intravascular ultrasound. In this study, we aim to investigate how well this method works in diagnosing coronary artery changes compared to the established methods.",[26],[75,76,77,78,79],"Heart transplantation","Cardiac allograft vasculopathy","photon counting computed tomography","Invasive coronary angiography","Intravascular ultrasound","NOT_YET_RECRUITING","2025-06-05",{"date":83,"type":33},"2025-06-13",{"date":85,"type":20},"2025-09-01",{"date":87,"type":20},"2027-08-31",{"name":89,"class":40},"Sahlgrenska University Hospital",1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":98,"enrollmentInfo":99,"targetDuration":101,"studyType":71,"phases":4,"briefSummary":102,"conditions":103,"keywords":104,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":90},"100270340","physiologic-assessment-of-microvascular-function-in-heart-transplant-patients-100270340","NCT02798731","Physiologic Assessment of Microvascular Function in Heart Transplant Patients","Physiologic Assessment of Microvascular Function and Its Impact on Cardiac Allograft Vasculopathy in Heart Transplant Patients: Prospective Registry and Pilot Study","Inclusion Criteria:\n\n* Subject over age of 18\n* Patients received heart transplant\n\nExclusion Criteria:\n\n* Patients with cardiogenic shock\n* Patients with unstable vital sign that precludes coronary angiography\n* Patients with major bleeding in last 3 months\n* Patients with active bleeding\n* Patients with coagulopathy\n* Patients with severe valvular heart disease\n* Patients who refused to provide informed consent","85 Years",{"count":100,"type":20},200,"6 Years","The aim of the study is to evaluate the impact of early microvascular disease assessed by coronary physiologic indices such as fractional flow reserve (FFR), coronary flow reserve (CFR), index of microvascular resistance (IMR) on future occurrence of cardiac allograft vasculopathy (CAV) in heart transplant recipients.",[26],[105,106,76,107,108,109],"Heart transplant","Microvascular dysfunction","Fractional flow reserve","Coronary flow reserve","Index of microvascular resistance","2025-03-12",{"date":112,"type":33},"2025-03-14",{"date":114,"type":33},"2016-05",{"date":116,"type":20},"2030-12",{"name":118,"class":40},"Samsung Medical Center",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":90},"100502760","microvascular-cardiac-allograft-vasculopathy-trial-100502760","NCT05826444","Microvascular Cardiac Allograft Vasculopathy Trial","Morphological and Functional Phenotype of Isolated Microvascular Cardiac Allograft Vasculopathy in Heart Transplant Recipients","mCAV","Inclusion Criteria:\n\n* able to consent\n* Written consent of the participant after clarification and sufficient time to think about participation\n* heart transplant recipient\n* Indication for routine invasive diagnostics or due to symptoms\n* Exercise tolerant in everyday life - cycling, climbing stairs at least 2 floors at a moderate speed without symptoms of exertion or dyspnea\n\nExclusion Criteria:\n\n* Addiction or other diseases that do not allow the patient to assess the nature and scope as well as possible consequences of the study\n* Patients or their legal guardians who do not sign the declaration of consent or who cannot fully understand it due to a lack of German language skills\n* Pregnant women, breastfeeding women\n* Severe comorbidities affecting the miRNA profile: diabetes mellitus, malignancy, end-stage renal disease with renal replacement therapy\n* Contraindication to the stress test: signs of cardiac decompensation, angina pectoris, dyspnea, hyperthyroidism, GFR \\\u003C30 ml\u002Fmin, peripheral arterial disease, pheochromocytoma, angle-closure glaucoma, prostate adenoma, paroxysmal tachycardia, tachycardia atrial fibrillation\n* Evidence of an acute rejection or local wall motion disturbances in the resting echocardiography",{"count":128,"type":20},50,"The aim of the mCAV study is a comprehensive characterization of the genetic, morphological and functional phenotype of isolated microvascular graft vasculopathy (mCAV) after orthotopic heart transplantation (OHT).\n\nThe utilized methods include dynamic echocardiography, magnetic resonance imaging, invasive microvascular resistance measurements, histology, cellular calcium-signaling and magnetocardiography as well as molecular genetic expression analysis (miRNA based).",[26],[132,133],"heart transplantation","cardiac allograft vasculopathy","2024-08-08",{"date":136,"type":33},"2024-08-12",{"date":138,"type":33},"2022-10-01",{"date":140,"type":20},"2025-12-31",{"name":142,"class":40},"German Heart Institute"]